Summary: The Case for QALY's: US Decision-
Making for Pharmaceuticals
Disadvantages?
Christopher Leibman
Sr. Director ­ Pharmacoeconomics
Elan Pharmaceuticals
What's wrong with QALYs, they seem so nice?
Apologies to R. Townsend
& Koala Bears
What's Wrong with QALY's - Common Criticisms
Historically cost-utility analysis was used to value
programs with widely different outcomes ­ often mis-
applied
Whose preferences should be used?
Can the stages of disease be adequately depicted so
utilities can be determined? Measurement is
problematic
May not ethically distribute healthcare ­ often left with
discussing appropriate thresholds
Methods...Others...

Source: Abagyan, Ruben - School of Pharmacy and Pharmaceutical Sciences, University of California at San Diego

Collections: Biology and Medicine